We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Relating Gene Expression to Multidrug Resistance

By Biotechdaily staff writers
Posted on 14 Sep 2004
Cancer researchers investigating the problem of multidrug resistance--development of resistance to anticancer drugs by tumor cells--have profiled the mRNA expression of the 48 known human ABC transporters in 60 diverse cancer cell lines to screen for anticancer activity and to relate gene expression to the effectiveness of anticancer drugs.

The ATP (adenotriphosphate)-binding cassette (ABC) genes represent the largest family of transmembrane proteins. More...
These proteins bind ATP and use the energy to drive the transport of various molecules across all cell membranes. Proteins are classified as ABC transporters based on the sequence and organization of their ATP-binding domains.

Investigators at the U.S. National Cancer Institute (Bethesda, MD, USA; www.nci.nih.gov) used real-time polymerase chain reaction (RT-PCR) technology to detect and quantify the expression of 48 ABC transporter genes in 60 diverse cancer cell lines. The expression of more than 68,500 genes was correlated with the growth inhibitory profiles of 1,429 candidate anticancer drugs.

Results published in the August 24, 2004, issue of Cancer Cell revealed 131 strongly inverse-correlated pairs, where cellular ABC gene expression was strongly correlated with decreased sensitivity to the drug. An unexpected finding was that expression of some ABC transporters, most notably MDR1, caused an increase in sensitivity to some drugs.

Senior author Dr. Michael Gottesman, chief of the laboratory of cell biology at NCI, said, "These results indicate that some of the ABC transporters whose function remains unknown can influence the response of cells to cancer treatment.”

The investigators recommended that research continue to identify other compounds that interact in this way with MDR1 and other ABC transporters to increase sensitivity to chemotherapeutic agents.




Related Links:
U.S.National Cancer Institute

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.